COMP <GO>
ORKA vs IDXX // FREE CASH FLOW YIELD
Oruka Therapeutics Inc. (NASDAQ) VS. IDEXX Laboratories Inc. (NASDAQ) • 15-METRIC TALLY: ORKA 4
— IDXX 7
▲ FREE CASH FLOW YIELD LEADER: IDXX
LAST: $95.43 (-1.49%) • MKT CAP: $6.41B
fcf-yield
-1.38%
LAST: $671.64 (+21.85%) • MKT CAP: $43.42B
fcf-yield
2.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. IDXX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORKA | IDXX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 61.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.80% | 29.60% | -48.40 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.38% | 2.33% | -3.71 | IDXX | /fcf-yield <GO> |
| Operating Margin | -6.80% | 31.60% | -38.40 | IDXX | /operating-margins <GO> |
| Net Profit Margin | -5.90% | 24.60% | -30.50 | IDXX | /net-margins <GO> |
| Revenue Growth (YoY) | -4.40% | 10.40% | -14.80 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 20.99 | +5.01 | ORKA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.0 | 50.5 | +16.50 | ORKA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.89 | +0.24 | ORKA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 39.8x | -11.80 | ORKA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $43.42B | -$37.01B | IDXX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORKA REV | IDXX REV | ORKA GROSS % | IDXX GROSS % | ORKA FCF | IDXX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $341.7M | $4.30B | — | 61.8% | -$88.4M | $1.06B |
| FY 2024 | $246.7M | $3.90B | — | 61.0% | -$58.0M | $808.1M |
| FY 2023 | $20.4M | $3.66B | — | — | -$5.0M | $741.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
IDXX // BETA 0.89